MURRAY HILL, N.J.--(BUSINESS WIRE)--Aug. 8, 2003--C. R. Bard, Inc.
(NYSE:BCR) today announced that Timothy M. Ring has succeeded William
H. Longfield as Chairman and Chief Executive Officer. Longfield, who
retired after 14 years with Bard, will remain on the Board of
Ring, 45, was elected Chairman and Chief Executive Officer,
effective August 8, 2003, by the Board of Directors in February. He
joined the company in 1992 as Vice President, Human Resources and was
elected Group Vice President, International in 1993. In 1997 he was
promoted to Group President with global responsibility for the
company's Vascular and Specialty Access businesses. Prior to joining
Bard, Ring spent ten years with Abbott Laboratories in both human
resources and general management. Ring also held management positions
at General Motors Corporation. He holds a B.S. in Industrial and Labor
Relations from Cornell University.
Longfield, 65, joined Bard in 1989 as Executive Vice President and
Chief Operating Officer and was Chairman and Chief Executive Officer
since 1995. During his tenure, Bard's revenues nearly doubled while
earnings more than tripled. Ring commented, "Bill has had a profound
effect on Bard over the last fourteen years. He leaves us in excellent
condition and well poised for the future. His leadership has set a
standard of unparalleled integrity in all that we do. I would like to
thank Bill on behalf of our employees, customers and shareholders for
his tremendous stewardship of the company."
The company also announced today that John H. Weiland has assumed
the role of President and Chief Operating Officer.
Weiland, 47, joined Bard in 1996 as Group Vice President. He was
promoted to Group President in 1997 with most recent responsibility
for Bard's global Surgical, Urological, and Endoscopic Technology
businesses. He was elected President and COO by the Board in February,
effective August 8, 2003. Prior to joining the company, Weiland was
Senior Vice President of Dentsply International. He served as
President and Chief Executive Officer of Pharmacia Diagnostics and
held management positions at American Hospital Supply and Baxter
Healthcare. He also served as a White House Fellow in the Office of
Management and Budget. Weiland received a B.S. in Biology from DeSales
University and an MBA from New York University.
Ring commented further, "I am honored and pleased to be taking
over the leadership of Bard as we approach our centennial year. This
is a great company, dedicated to delivering innovative products that
sustain and enhance the lives of patients around the world. Our senior
management transition has gone very smoothly. Together with John
Weiland and our dedicated employees, we will build on our legacy of
quality, integrity, service and innovation. I could not be more
excited about the future and the opportunities that lie ahead for
C. R. Bard, Inc., (www.crbard.com) headquartered in Murray Hill,
N.J., is a leading multinational developer, manufacturer, and marketer
of innovative, life-enhancing medical technologies in the fields of
vascular, urology, oncology, and surgical specialty products.
CONTACT: C. R. Bard, Inc.
Eric J. Shick, 908-277-8413
Holly P. Glass, 703-754-2848
SOURCE: C. R. Bard, Inc.